Show simple item record

dc.creatorChahuán Y,Marco
dc.creatorCorradi H,Luis
dc.creatorRomán A,Oscar
dc.creatorBravo G,Cecilia
dc.date2000-01-01
dc.date.accessioned2019-05-02T21:10:42Z
dc.date.available2019-05-02T21:10:42Z
dc.identifierhttps://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0034-98872000000100008
dc.identifier.urihttp://revistaschilenas.uchile.cl/handle/2250/81048
dc.descriptionBackground: Third generation beta blockers have an intrinsic simpatico-mimetic activity and are cardioselective. Therefore, they should not have adverse bronchial effects and could even have a slight bronchodilator activity. Aim: To test the efficacy and safety of celiprolol in hypertensive patients with chronic obstructive lung disease. Patients and methods: Uncomplicated hypertensive patients with chronic obstructive lung disease received celiprolol during 12 weeks. They were subjected to monthly clinical assessment and ventilatory function was measured on the basal period and at the end of the trial. Results: During the study period, blood pressure fell significantly from 179±6/112±8 to 161±4,7/98±1.6 mmHg. No changes were observed in forced expiratory volume in 1 s or in forced expiratory flow between 25 and 75% of the vital capacity. No subjective changes in respiratory function were reported during the trial. Conclusions: No changes in ventilatory function were observed in these patients with chronic obstructive lung disease, treated with celiprolol during 12 weeks. (Rev Méd Chile 2000; 128: 59-63)
dc.formattext/html
dc.languagees
dc.publisherSociedad Médica de Santiago
dc.relation10.4067/S0034-98872000000100008
dc.rightsinfo:eu-repo/semantics/openAccess
dc.sourceRevista médica de Chile v.128 n.1 2000
dc.subjectAdrenergic beta-antagonists
dc.subjectCeliprolol
dc.subjectLung diseases, obstructive
dc.titleSeguridad y eficacia de celiprolol en hipertensos con enfermedad pulmonar obstructiva crónica


This item appears in the following Collection(s)

Show simple item record